Press releases
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
More ▼
Key statistics
On Friday, Seres Therapeutics Inc (1S9:DUS) closed at 0.5972, 21.48% above the 52 week low of 0.4916 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.7164 |
---|---|
High | 0.75 |
Low | 0.5954 |
Bid | 0.563 |
Offer | 0.6074 |
Previous close | 0.8996 |
Average volume | 30.00 |
---|---|
Shares outstanding | 151.45m |
Free float | 142.81m |
P/E (TTM) | -- |
Market cap | 162.05m USD |
EPS (TTM) | -0.6062 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 18:30 BST.
More ▼